The Pharma Letter2h
FDA warns of rare but serious allergic reaction with glatiramer
The US Food and Drug Administration (FDA) is warning about the risk of a rare but serious allergic reaction with the medicine ...
The Pharma Letter3h
ArriVent inks ADC licensing deal with Lepu Biopharma
US clinical-stage biotech ArriVent BioPharma has entered into an exclusive license agreement with Shanghai-based Lepu ...
The Pharma Letter4h
Ascentage Pharma sets terms for $149 million US IPO
Suzhou, China-based Ascentage Pharma revealed that it plans to raise $149 million by offering 7.3 million American Depositary ...
The Pharma Letter6h
Funding for Arctic’s anti-amyloid treatment for rare and common forms of dementia
Icelandic drug discovery and development company Arctic Therapeutics has announced the successful closing of a 26.5 million ...
The Pharma Letter6h
FDA accepts Replimune’s melanoma candidate for priority review
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...
The Pharma Letter7h
FDA sends Sanofi warning letter over quality violations
The FDA issues a warning letter to Sanofi over manufacturing violations at its Massachusetts site, citing contamination and ...
The Pharma Letter7h
Renewed Kyverna sets new course with fresh CMO
Kyverna Therapeutics appoints Naji Gehchan as CMO to advance KYV-101, its CD19-directed CAR-T therapy for autoimmune diseases ...
The Pharma Letter5h
Clinical hold follows CRL for Atara
T-cell immunotherapy company Atara Biotherapeutics closed 8% lower on Tuesday, having lost 41% of its stock market value on ...
The Pharma Letter7h
Recipharm and Spektus team up to supply oral CNS drugs
Spektus Pharma, a Quebec-based specialty pharma company developing therapeutics for the treatment of CNS disorders, has ...
The Pharma Letter7h
NICE recommends two AstraZeneca lung cancer treatments
UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...
The Pharma Letter5h
Positive Phase II trial results for Coherus' casdozokitug
Shares of Coherus BioSciences rose 4.5% to $1.8 in pre-market activity after it released positive med-stage results for its ...
The Pharma Letter2h
Revocation of Biden AI order will impact life sciences
The US President repeals Biden's 2023 executive order on AI safeguards, impacting healthcare and drug research. The rollback eases compliance for AI developers but raises concerns over risks of unsafe ...